公开(公告)号：US20230263888A1

公开(公告)日：2023-08-24

申请号：US17958041

申请日：2022-09-30

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel GETTS

IPC: A61K39/00 ,  A61K38/18 ,  A61K38/20 ,  A61K38/17 ,  A61K39/39 ,  A61K31/155 ,  A61P37/06

CPC classification number: A61K39/4614 ,  A61K39/46433 ,  A61K39/0008 ,  A61K38/1841 ,  A61K38/2066 ,  A61K38/1761 ,  A61K39/39 ,  A61K31/155 ,  A61P37/06 ,  A61K2039/55516 ,  A61K2039/5256 ,  A61K2039/523 ,  A61K2239/39

Abstract: Methods and compositions for treating autoimmune diseases and conditions using engineered myeloid cells.

公开(公告)号：US20220378824A1

公开(公告)日：2022-12-01

申请号：US17514828

申请日：2020-04-30

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel GETTS ,  Yuxiao Wang

IPC: A61K35/15 ,  C07K14/705 ,  A61P35/00 ,  C12N5/0786 ,  C12N15/62 ,  C12N9/12

Abstract: The present disclosure provides compositions and methods for making and using engineered phagocytic cells that express a chimeric antigen receptor having an enhanced phagocytic activity for immunotherapy in cancer or infection.

公开(公告)号：US20240139314A1

公开(公告)日：2024-05-02

申请号：US18486563

申请日：2023-10-13

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel GETTS ,  Yuxiao WANG

IPC: A61K39/395 ,  A61K31/407 ,  A61K31/4709 ,  A61K31/4995 ,  C07K14/47 ,  C07K14/705 ,  C07K14/735 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N15/85

CPC classification number: A61K39/3955 ,  A61K31/407 ,  A61K31/4709 ,  A61K31/4995 ,  C07K14/47 ,  C07K14/70535 ,  C07K14/70596 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/303 ,  C07K16/32 ,  C12N15/85 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/50 ,  C12N2800/107

Abstract: The present disclosure provides compositions and methods for making and using engineered myeloid cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, wherein the chimeric receptor is encoded by a recombinant nucleic acid.

公开(公告)号：US20220152199A1

公开(公告)日：2022-05-19

申请号：US17590504

申请日：2022-02-01

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel GETTS ,  Yuxiao Wang ,  Bruce McCreedy, JR.

IPC: A61K39/395 ,  A61K9/127 ,  A61K38/17 ,  A61K9/00 ,  A61P35/00

Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

公开(公告)号：US20240139241A1

公开(公告)日：2024-05-02

申请号：US18492345

申请日：2023-10-23

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel GETTS ,  Bruce J. McCreedy, JR. ,  Michele Luise Gerber ,  Thomas Etienne Prod’homme

IPC: A61K35/15 ,  A61K31/4995 ,  A61K31/675 ,  A61K31/7076 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K35/15 ,  A61K31/4995 ,  A61K31/675 ,  A61K31/7076 ,  A61K39/4614 ,  A61K39/464429 ,  A61P35/00 ,  C07K16/2896 ,  A61K2239/15 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/48

Abstract: Compositions and methods for therapeutic use of engineered myeloid cells are described. Methods for increasing therapeutic effectiveness of immune cells by use of an immune cell inhibitory agent prior to therapy is described. Effective use of myeloid cells in combination therapy is described.

公开(公告)号：US20220241428A1

公开(公告)日：2022-08-04

申请号：US17618349

申请日：2020-06-11

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel GETTS ,  Yuxiao Wang

IPC: A61K47/68 ,  A61K47/65 ,  A61K47/54 ,  A61K47/55

Abstract: The present disclosure provides compositions and methods for making and using therapeutic agents comprising myeloid cell specific engagers, used for immunotherapy of cancer or infection.

公开(公告)号：US20240182543A1

公开(公告)日：2024-06-06

申请号：US18516278

申请日：2023-11-21

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel GETTS ,  Yuxiao WANG

IPC: C07K14/735 ,  A61K48/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C12N15/113 ,  C12N15/86

CPC classification number: C07K14/70535 ,  A61K48/0066 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K14/70596 ,  C12N15/113 ,  C12N15/86 ,  C07K2319/03 ,  C12N2310/141 ,  C12N2740/15043

Abstract: Compositions and methods for making and using engineered myeloid cells that express a chimeric fusion protein for immunotherapy and compositions and methods for making and using engineered T cells that express a chimeric antigen receptor for immunotherapy.

公开(公告)号：US20230364266A1

公开(公告)日：2023-11-16

申请号：US18313126

申请日：2023-05-05

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel GETTS ,  Yuxiao Wang ,  Namita Bisaria ,  Inna Shcherbakova ,  Socheata Ly

IPC: A61K48/00 ,  C12N15/85 ,  C12N15/90 ,  A61K31/711 ,  A61K31/713 ,  A61K38/17 ,  A61K38/45 ,  A61K38/46 ,  A61K39/395 ,  C07K14/725 ,  C07K16/32 ,  C12N9/12 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113

CPC classification number: A61K48/005 ,  C12N15/85 ,  C12N15/90 ,  A61K31/711 ,  A61K31/713 ,  A61K38/1774 ,  A61K38/45 ,  A61K38/465 ,  A61K39/39558 ,  C07K14/7051 ,  C07K16/32 ,  C12N9/1276 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  C12N15/907 ,  C12Y207/07049 ,  C12N2800/90 ,  C12N2310/20 ,  A61K48/00 ,  C07K2319/03 ,  C07K2319/09 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2310/14 ,  C12N2320/31 ,  C12N2800/80 ,  C12N2830/50 ,  C12N2840/203

Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.

公开(公告)号：US20230364265A1

公开(公告)日：2023-11-16

申请号：US18313087

申请日：2023-05-05

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel GETTS ,  Yuxiao Wang ,  Namita Bisaria ,  Inna Shcherbakova ,  Socheata Ly

IPC: A61K48/00 ,  C12N15/85 ,  C12N15/90 ,  A61K31/711 ,  A61K31/713 ,  A61K38/17 ,  A61K38/45 ,  A61K38/46 ,  A61K39/395 ,  C07K14/725 ,  C07K16/32 ,  C12N9/12 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113

CPC classification number: A61K48/005 ,  A61K31/711 ,  A61K31/713 ,  A61K38/1774 ,  A61K38/45 ,  A61K38/465 ,  A61K39/39558 ,  C07K14/7051 ,  C07K16/32 ,  C12N9/1276 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  C12N15/85 ,  C12N15/90 ,  C12N15/907 ,  C12Y207/07049 ,  A61K48/00 ,  C07K2319/03 ,  C07K2319/09 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2320/31 ,  C12N2800/80 ,  C12N2800/90 ,  C12N2830/50 ,  C12N2840/203

Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.

公开(公告)号：US20240148785A1

公开(公告)日：2024-05-09

申请号：US18500556

申请日：2023-11-02

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel GETTS ,  Patrick Mendes TAVARES

IPC: A61K35/15 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C12N5/078 ,  C12N15/85

CPC classification number: A61K35/15 ,  A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464429 ,  A61P35/00 ,  C07K14/70596 ,  C12N5/0634 ,  C12N15/85 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/30

Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.